16 September 2026 editorial review · Trial
Islet transplantation with recipient Tregs or donor bone marrow: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT05973734; ENROLLING_BY_INVITATION; updated 2026-06-08; enrollment 24 (ESTIMATED); results not posted.
Endpoint comparison: Occurrence of Grade 3 to 5 cytokine release syndrome / acute infusion reaction after Treg administration infusion reaction after Treg administration (within 3 months); Occurrence of grade 4 or greater adverse events of islet transplantation (Within two years); Number of patients who receive Treg infusions (Arm1) or Donor Derived Vertebral Bone Marrow (Arm2) and islet transplantation (feasibility) (Within two years).
Sources for this record: NCT05973734: Islet transplantation with recipient Tregs or donor bone marrow (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.